Ironwood Pharmaceuticals (NASDAQ:IRWD) : Zacks Investment Research ranks Ironwood Pharmaceuticals (NASDAQ:IRWD) as 3, which is a Hold recommendation. 4 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 4 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 8 research analysts is 2, which indicates as a Buy.
Ironwood Pharmaceuticals (NASDAQ:IRWD) : 7 investment research analysts covering Ironwood Pharmaceuticals (NASDAQ:IRWD) have an average price target of $12.57 for the near short term. The highest target price given by the Brokerage Firm to the stock is $16 and the lowest target is $10 for the short term. Analysts expect the variance to be within $2.7 of the average price.
Company shares have received an average consensus rating of Hold for the current week Also, Cowen & Company upgrades its rating on Ironwood Pharmaceuticals (NASDAQ:IRWD). Analysts at the Cowen & Company have a current rating of Outperform on the shares. The shares were previously rated Market Perform. The rating by the firm was issued on April 6, 2016.
Ironwood Pharmaceuticals (NASDAQ:IRWD): stock turned positive on Tuesday. Though the stock opened at $12.45, the bulls momentum made the stock top out at $13.15 level for the day. The stock recorded a low of $12.45 and closed the trading day at $12.8, in the green by 5.09%. The total traded volume for the day was 1,494,992. The stock had closed at $12.18 in the previous days trading.
In an insider trading activity,The director of Ironwood Pharmaceuticals Inc, Olanoff Lawrence S sold 2,200 shares at $12.92 on June 3, 2016. The Insider selling transaction had a total value worth of $28,424. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Ironwood Pharmaceuticals, Inc. is a pharmaceutical company. The Company has a product, linaclotide, which is available in the United States and Mexico under the brand name LINZESS, and is available in European countries and Canada under the brand name CONSTELLA. Linaclotide is also being developed and commercialized in other parts of the world by certain of its partners. Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders. The Company in collaboration with Astellas Pharma Inc. (Astellas) is developing linaclotide for the treatment of patients with IBS-C.